AlphaCentric Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
Other funds holding ALNY
AlphaCentric Advisors's ALNY Position: Q3 2026 in Review
AlphaCentric Advisors increased its Alnylam Pharmaceuticals (ALNY) stake by 3% in Q3 2026, buying an estimated $10.7K and bringing the position to 1,432 shares worth $353K. The position accounts for 0.31% of the portfolio, ranked #101.
AlphaCentric Advisors first reported a position in ALNY in Q4 2025 and has held it in 4 quarters since. The position peaked at $515K in Q4 2025. 640 funds tracked by Wall St. Rank hold ALNY as of Q3 2026.
- AlphaCentric Advisors held 1,432 shares of Alnylam Pharmaceuticals worth $353K as of Q3 2026.
- AlphaCentric Advisors bought 42 Alnylam Pharmaceuticals shares in Q3 2026, an estimated $10.7K.
- Alnylam Pharmaceuticals made up 0.31% of AlphaCentric Advisors's portfolio in Q3 2026, its #101 holding.
- AlphaCentric Advisors first reported a position in Alnylam Pharmaceuticals in Q4 2025 and has held it in 4 quarters since.
- AlphaCentric Advisors's Alnylam Pharmaceuticals position peaked at $515K in Q4 2025.
- 640 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2026.
Based on AlphaCentric Advisors's 13F filing for Q3 2026, filed 3 Nov 2026.